Answer
In Panorama 1, fatigue occurred in 41.2% of patients with multiple myeloma receiving Farydak (panobinostat) with bortezomib and dexamethasone, with CTC grade 3 fatigue in 15.7% and grade 4 in 1.3%.
Sources for this answer
- Farydak 10mg hard capsulespharmaand GmbH · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked